Tempus AI, a technology company leading the adoption of AI to advance precision medicine and patient care, has announced a collaboration with The Abrams Research Center on Neurogenomics at Northwestern University Feinberg School of Medicine. This multi-year collaboration aims to harness AI for rapid discovery and innovation in Alzheimer’s disease research.
The collaboration leverages Tempus’ AI-powered data analytics platform, Lens, to analyse and restructure the centre’s repository of genomic data. Together, the centre and Tempus teams will work to uncover genomic patterns that have the potential to advance the understanding of Alzheimer’s disease, investigate the gene and cell types affected, enable the development of new therapeutics and accelerate the creation of novel clinical applications. By harnessing Lens’ advanced AI capabilities, the collaboration aims to generate actionable insights that drive the discovery of targeted therapies and significantly improve patient outcomes.
“We are excited to collaborate with the Abrams Research Center on Neurogenomics to confront one of the most complex and pressing medical challenges of our time,” said Ryan Fukushima, Chief Operating Officer at Tempus. “By integrating our AI platform with the centre’s pioneering work in neurogenomics, we are opening new avenues for discovery. Together, we strive to advance research for Alzheimer’s and bring hope and tangible impact to patients and families affected by this devastating disease.”
